Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

Inclusion Criteria: * Males and females at the age or over 18 years of age. * With primary hyperlipidemia or mixed dyslipidemia. * Treated with stable daily dose of statins * At high or very high risk of incurring a CV event * Fasting LDL-C \>=70 mg/dL (1.81 mmol/L) for subjects on the highest approved dose of statins; Fasting LDL C \>=77 mg/dL (1.99 mmol/L) for subjects not on highest approved dose. * Fasting TG ≤400 mg/dL (4.51 mmol/L) Exclusion Criteria: * Prior exposure to bococizumab or other investigational PCSK9 inhibitor * NYHA class IV, or Left Ventricular Ejection Fraction \<25% * Poorly controlled hypertension * History of hemorrhagic stroke or lacunar infarction resulting in a stroke * Untreated hyperthyroidism or TSH \>1 × ULN * Undergoing apheresis or have planned start of apheresis.